Weekly Spotlight - 31.10.24

Community

We want to hear your story!

Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!

In the News

Gilead's Hopeful Leap with Anito-cel CAR-T Therapy Data

Gilead Sciences is eagerly awaiting the results of a pivotal trial for anito-cel, a promising CAR-T therapy for multiple myeloma, developed with Arcellx. Success could position it as a safer alternative to Carvykti, potentially generating multibillion-dollar sales. The data release is anticipated on 5th November.

CAR T-Cell Therapy Success in Myeloma with Kidney Failure

Two patients with multiple myeloma and kidney failure on dialysis successfully received CAR T-cell therapy at Memorial Sloan Kettering. Adjusted treatment led to positive responses without severe side effects. This suggests CAR T-cell therapy could be viable for similar patients, offering hope despite their exclusion from major trials.

European Commission Approves New Darzalex Regimen for Multiple Myeloma Treatment

The European Commission has approved Johnson & Johnson's Darzalex SC regimen for newly diagnosed multiple myeloma, offering hope to patients. This treatment, combined with other drugs, significantly reduces disease progression. The approval marks a positive step in improving care and outcomes for those affected by this challenging condition.

Elranatamab Approved for Wider Use in Multiple Myeloma Treatment

NICE has recommended elranatamab for multiple myeloma patients in England and Wales, lifting previous restrictions. It's available through the Cancer Drugs Fund for those with relapsed and refractory conditions after three treatments. This offers hope while more evidence on its effectiveness is gathered.